Ustekinumab 130mg/26ml solution for infusion vials
NHS hospitals in England used £62,601,400 of indicative cost of Ustekinumab 130mg/26ml solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 44.9% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ustekinumab 130mg/26ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ustekinumab 130mg/26ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £2,157,735 |
| Oxford University Hospitals Nhs Ft | £1,730,482 |
| Western Sussex Hospitals Nhs Found Trust | £1,672,513 |
| University College London Foundation Tr | £1,554,428 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,530,811 |
| University Hpls Of Leicester Nhs Trust | £1,524,370 |
| Manchester University Nhs Ft | £1,434,196 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,378,374 |
| University Hospital Southampton Nhs Ft | £1,376,227 |
| Leeds Teaching Hpls Nhs Trust | £1,122,881 |
The primary-care picture
Ustekinumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Ustekinumab medicine page.